Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Morrison, Jo ^a   Swanton, A ^b   Collins, S ^b   Kehoe, S ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Antineoplastic agents therapeutic use ; Chemotherapy, adjuvant; Cystadenocarcinoma *drug therapy; pathology; *surgery ; Cystadenocarcinoma, serous drug therapy; pathology; surgery ; Neoadjuvant therapy methods

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; GASTROINTESTINAL TOXICITY; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TOXICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

EID: 44449167562     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005343.pub2     Document Type: Review

References (65)

1. Liu 2004 {published data only} Liu EL, Mi RR. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Chinese Medical Journal (Engl) 2004;117(10): 1547-51.
2. Ansquer 2001 Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al.Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001;91(12):2329-34.
3. Baekelandt 2003 Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. International Journal of Gynecological Cancer 2003;13 Suppl 2:163-8.
4. Bertelsen 1990 Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecologic Oncology 1990;38(2):203-9.
5. Bidzinski 2005 Bidzinski M, Danska-Bidzinska A, Ziólkowska-Seta I, Derlatka P, Sobiczewski P, Raczynski P. Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy - preliminary results. European Journal of Gynaecological Oncology 2005;26(4):423-6.
6. Bristow 2001 Bristow R, Tomacruz, RS, Armstrong, DK, Trimble, EL, Montz, FJ. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis of 6,848 patients. Proceedings of the American Society of Clinical Oncology 2001; 20 (1): (Abstract 807) 202a. 2001.
7. Chambers 1990 Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecologic Oncology 1990;37(3):327-31.
8. Chan 2003 Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecologic Oncology 2003;88(1):9- 16.
9. Deval 2003 Deval B PJ, Platini C, Combe M, Boiron C, Mignot L, Geay J, et al.Surgery: An option for patients with FIGO stage IV ovarian cancer treated by platinum-paclitaxel-based regimen? A GINECO study. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:452; Abstract 1817.
10. Dutta 2005 Dutta T, Sharma H, Kumar L, Dinda AK, Kumar S, Bhatla N, et al.Neoadjuvant chemotherapy for epithelial ovarian cancer - role of apoptosis. Cancer chemotherapy and pharmacology 2005;56(4):427-35.
11. Evdokimova 1982 Evdokimova NI, Grigorova TM. [Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer]. Voprosy Onkologii 1982;28(7):28-34.
12. Fanfani 2003 Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, et al.Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 2003;65(4):316-22.
13. Jacob 1991 *Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecologic Oncology 1991;42(2):146-50.
14. Janga 2003 Janga D, Kumar, L, Kumar, S, Shukla, NK, Thulkar, S, Singh, R. Neoadjuvant chemotherapy followed by debulking surgery versus up-front surgery followed by chemotherpay in advanced epithelial ovarian carcinoma: A prospective randomized study. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:487; Abstract 1957.
15. Kayikcioglu 2000 Kayikcioglu F, Kose, MF, Boran, N, Ozdas, E, Ozgul N, Tulunay G. Neoadjuvant chemotherapy in advanced stage ovarian carcinoma. VIII Meeting of the International Gynecologic Cnacer Society. Buenos Aires, Argentina: 2000:Abstract 48.
16. Kayikcioglu 2001 Kayikcioglu F, Kose MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. International Journal of Gynecological Cancer 2001;11(6):466-70.
17. Kuhn 2001 Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al.Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001;92(10):2585-91.
18. Kumar 2003 Kumar L, Janga D, Berge S, Gupta S, Kumar S, Bhatla N, Kochupillai VEML. Neoadjuvant chemotherapy in stage III&IV epithelial ovarian carcinoma (EOC). Journal International Medical Sciences Academy 2003;16(2):89-92.
19. Lawton 1989 Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics and Gynecology 1989;73(1):61-5.
20. Lim 1993 Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clinical Oncology (Royal College of Radiologists (Great Britain)) 1993; 5(4):198-202.
21. Liu 1995 Liu S, Jiang D, Xu G. Advanced ovarian cancer: Combination chemotherapy and cytoreductive surgery. Acta Academiae Medicinae Hubei 1995;16(4):343-4.
22. Loizzi 2005 Loizzi V, Cormio G, Resta L, Rossi CA, Di Gilio AR, Cuccovillo A, et al.Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. International Journal of Gynecological Cancer 2005;15 (2):217-23.
23. Lotze 1987 Lotze W, Richter P, Sarembe B. [Intra-arterial chemotherapy in advanced ovarian cancers. 2. Therapeutic results in relation to prognostic factors]. Zentralblatt für Gynäkologie 1987;109(9):578-85.
24. Lyngstadaas 2005 Lyngstadaas A, Ekanger R, Hagen B, Himmelmann A, Iversen OE, Iversen T, et al.[Primary treatment of ovarian cancer]. Tidsskrift for den Norske Laegeforening 2005;125(3):278-81.
25. Malzoni 1993 Malzoni M, Palagiano, A, Palmese, A. Neo-adjuvant chemotherapy in ovarian carcinoma (case report). Rassegna Internazionale di Clinica e Terapia 1993;73(7):309-12.
26. Mazzeo 2003 Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecologic Oncology 2003;90(1):163-9.
27. Morice 2003 Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al.Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Journal of the American College of Surgeons 2003;197(6):955-63.
28. Negretti 1988 Negretti E, Zambetti M, Luciani L, Gianni L. Timing of surgery and the role of cytoreductive chemotherapy in patients with advanced ovarian carcinoma. Tumori 1988;74(5):567-72.
29. Onnis 1996 Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. European Journal of Gynaecologic Oncology 1996;17(5):393-6.
30. Recchia 2001 Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. European Journal of Gynaecological Oncology 2001;22(4):287-91.
31. Redman 1994 Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology 1994; 101(2):142-6.
32. Salzer 1990 Salzer H, Genger H, Gober S, Barrada M, Vavra N, Sevelda P. [Surgery in the treatment concept of epithelial ovarian cancer]. Gynäkologische Rundschau 1990;30 Suppl 1:26-9.
33. Schwartz 1994 Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology 1994;53(1):33-7.
34. Schwartz 1999 Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecologic Oncology 1999;72(1):93-9.
35. Shibata 2003 Shibata K, Kikkawa F, Mika M, Suzuki Y, Kajiyama H, Ino K, et al.Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors. International Journal of Gynecological Cancer 2003;13(5):587-92.
36. Shimizu 1993 Shimizu Y, Hasumi K. [Treatment of stage III and IV ovarian cancer -is neoadjuvant chemotherapy effective?]. Nippon Sanka Fujinka Gakkai Zasshi 1993;45(9):1007-14.
37. Sun 2000 Sun T, Feng Y, Zhu Y, Zheng Y. Therapeutic strategy in the management of stage II - IV epithelial ovarian carcinoma. Chinese Medical Journal 2000;113(7):625-7.
38. Surwit 1999 Surwit E, Childers, J. Cytoreductive surgery in advanced ovarian cancer with or without neoadjuvant chemotherapy. Gynecologic Oncology 1999;72(3):468.
39. Trope 1997 Trope C. Primary debulking surgery is not an independent prognostic factor in advanced stage IIIC ovarian carcinoma. Gynecologic Oncology 1997;64(2):357.
40. Ushijima 2002 Ushijima K, Ota S, Komai K, Matsuo G, Motoshima S, Honda S, et al.Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. International Surgery 2002;87(3):185-90.
41. van der Burg 1995 van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al.The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. New England Journal of Medicine 1995;332(10):629-34.
42. Vergote 1998 Vergote I, De Wever IW, Tjalma W, Van Gramberen M, Decloedt J, van Dam, P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology 1998;71(3):431-6.
43. Vergote 2000 Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M, van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology 2000;27(3 Suppl 7):31-6.
44. Vrscaj 2002 Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. European Journal of Gynaecological Oncology 2002;23(5):405-10.
45. Yuzeng 1998 Yuzeng F TS. Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer. Chinese Medical Journal 1998;111(8):722-5.
46. CHORUS 2003 Kehoe S, Wheeler S. CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. London: http: //www.ctu.mrc.ac.uk/studies/documents/protocol.pdf, 2003.
47. EORTC 55971 Vergote I, Pecorelli S, Stuart G. Intergroup Study (EORTC 55971/NCIC OV13). Randomized Phase III study comparing up-front debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/ clinicaltrials/EORTC-55971 2003.
48. Kumar 2006 Kumar L, Hariprasad R, Kumar S, Bhatla N, Shukla N, Thulkar S, Singh R. Neoadjuvant chemotherapy in advanced epithelial ovarian oancer (EOC): A phase III randomized study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. (June 20 Supplement). 2006; Vol. 24:18S.
49. Allen 1995 Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. European Journal of Gynaecologic Oncology 1995;16(5):349-56.
50. Bristow 2002 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20(5):1248-59.
51. Burghardt 1991 Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecologic Oncology 1991;40(2):103-6. [MEDLINE: 91184633].
52. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
53. Griffiths 1975 Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monograph 1975;42:101-4. [MEDLINE: 77056303].
54. Griffiths 1978 Griffiths CT, Fuller AF. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. The Surgical Clinics of North America 1978;58(1):131-42. [MEDLINE: 78159957].
55. Hoskins 1992 Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 1992;47(2):159-66. [MEDLINE: 93106491].
56. Hunter 1992 Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?. American Journal of Obstetrics and Gynecology 1992;166(2):504-11. [MEDLINE: 92160883].
57. Kehoe 1994 Kehoe S, Powell J, Wilson, S, Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. British Journal of Cancer 1994;70(5):1014-7.
58. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [MEDLINE: 99120172].
59. Petru 1991 Petru E, Pickel H, Tamussino K, Lahousen M, Heydarfadai M, Posawetz W, et al.Pretherapeutic scalene lymph node biopsy in ovarian cancer. Gynecologic Oncology 1991;43(3):262-4. [MEDLINE: 92090796].
60. Quinn 2001 Quinn M, Babb P, Brock A, Jones J. Cancer Trends in England and Wales. London: The Stationery Office, 2001.
61. Rose 2004 Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al.Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine 2004;351(24):2489-97.
62. Shepherd 1989 Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889-92. [MEDLINE: 89375209].
63. Shepherd 1990 Shepherd JH. Surgical management of ovarian cancer. In: Shepherd JH, Monaghan JM editor(s). Clinical Gynaecological Oncology. Second Edition. Oxford: Blackwell Scientific Publications, 1990: 218-46.
64. Trimbos 2003 Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al.International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute 2003;95 (2):105-12.
65. Venesmaa 1992 Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstetrics and Gynecology 1992;79(2):168-72.